Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 6/20 | 0.48 |
| ▸ | CCND1 | P24385 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070516 | 0.86 | PDPK1 (0.52) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL3938271 | 0.85 | TYK2 (0.54) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL3937311 | 0.83 | STK17B (0.53) | PDPK1RPS6KB1LMNAMAPTMAPK1 | |
| SCHEMBL4067717 | 0.83 | FLT1 (0.54) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL4066406 | 0.82 | LMNA (0.53) | PDPK1RPS6KB1LMNAMAPTMAPK1 | |
| SCHEMBL4074426 | 0.82 | PDPK1 (0.48) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL3929003 | 0.82 | LMNA (0.49) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL3927158 | 0.81 | CYP1A2 (0.63) | CDK4CCND1LMNAMAPTMAPK1 | |
| SCHEMBL3937743 | 0.81 | TYK2 (0.51) | PDPK1RPS6KB1CDK4CCND1LMNA | |
| SCHEMBL4076692 | 0.80 | CYP1A2 (0.55) | PDPK1RPS6KB1LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009007421-A1 | INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | PDPK1 1704/4885RPS6KB1 1211/4885CDK4 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.